Bioniche spins out human health subsidiary

Guest Contributor
March 14, 2013

Bioniche Life Sciences Inc, Belleville ON, is creating a wholly own subsidiary from its core human health technology to attract external investment and boost the value of the corporation. Bioniche Therapeutics Corp will function as a standalone unit with its own CEO and will seek external revenues through private equity or licensing income derived from Urocidin, its flagship late-stage therapeutic bladder cancer product.The global rights to Urocidin were returned to Bioniche earlier this year by Endo Pharmaceuticals, Chadds Ford PA after it discontinued its Phase III clinical trial. Uridicin's development was assisted with a $9.6-million repayable loan from Technology Partnerships Canada (now Industry Canada's Industrial Technologies Office)….


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.